Skip to content
lifestyle.menstyle1.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tvardi Therapeutics
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
July 30, 2026
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
July 7, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Events
May 24, 2026
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
May 8, 2026
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
April 2, 2026
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
March 31, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
February 13, 2026